What the Phase 2 Trial Arms Looked Like The table below records what was administered in that trial and the least-squares mean changes reported at 48 weeks a record of past research, not a protocol
Researchers are also exploring its application in treating obesity independently of diabetes, pointing toward broader therapeutic implications
What diseases are treated using receptor agonists
Why Trust Everyday Health Amy Fischer, MS, RD, CDN Author Amy Fischer, MS, RD, CDN, is the former senior nutrition editor at Health
The specific system matters less than the consistency of never hitting the same spot twice in a row
Off-Label Use: Some medications are prescribed off-label for weight loss: Semaglutide (Ozempic): FDA-approved for type 2 diabetes (not weight loss) Identical to Wegovy but different indication Commonly prescribed off-label for weight loss Same effectiveness as Wegovy Tirzepatide (Mounjaro): FDA-approved for type 2 diabetes (not weight loss) Identical to Zepbound but different indication Prescribed off-label for weight loss before Zepbound approval Same effectiveness as Zepbound Metformin: Diabetes medication sometimes used for weight loss Produces only 1-3% weight loss Not FDA-approved for weight loss Generally not recommended as primary weight loss medication The Current State of Weight Loss Medication: Clear Winners: GLP-1 receptor agonists (especially tirzepatide and semaglutide) have become the gold standard for medical weight loss, producing results previously unattainable with medication alone
